MedTrace Logo

Efficacy Study of Dextromethorphan to Treat Rheumatoid Arthritis

NCT02368093 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2015-03-31

Study results available
· View outcomes & findings →

Summary

Rheumatoid arthritis were randomized to a 6-month treatment of oral dextromethorphan hydrobromide or placebo as an add-on therapy to traditional disease-modifying anti-rheumatic drugs (DMARDs). Disease activity were assessed.

Conditions

Interventions

DRUG

Dextromethorphan hydrobromide

120mg per day with once daily dose taken after breakfast for 6 months

Sponsors & Collaborators

  • TSH Biopharm Corporation Limited

    collaborator INDUSTRY

  • Taichung Veterans General Hospital

    lead OTHER

Principal Investigators

  • Der-Yuan Chen, M.D., Ph.D. · Division of Allergy,Immunology and Rheumatology, Taichung Veterans General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-09-30
Completion
2012-09-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02368093 on ClinicalTrials.gov